Sacituzumab Govitecan for Breast Cancer

This trial explores a new treatment option called sacituzumab govitecan (an antibody-drug conjugate) for individuals with advanced breast cancer that is hormone-sensitive and HER2-negative. The aim is to determine if this treatment can benefit patients whose cancer has progressed despite previous therapies, such as CDK4/6 inhibitors and trastuzumab deruxtecan. Researchers seek to understand the effectiveness of sacituzumab govitecan when used after trastuzumab deruxtecan. Suitable candidates have breast cancer deemed incurable by surgery but have received specific prior therapies, including chemotherapy and trastuzumab deruxtecan. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that patients with stable doses of anticonvulsants and corticosteroids can participate, suggesting some medications may be allowed.

Previous studies have shown that sacituzumab govitecan (SG) is generally well-tolerated by breast cancer patients. Research indicates that SG's safety profile aligns with earlier findings, revealing no new safety concerns. A detailed review and analysis demonstrated that SG is effective and tolerable, with only minor side effects reported. While some side effects may occur, they are usually manageable. Overall, SG has been used safely in other cancer patients, supporting its use in ongoing research.¹²³⁴⁵

Sacituzumab Govitecan is unique because it combines an antibody with a cancer-killing drug, specifically targeting the Trop-2 protein found on many breast cancer cells. This targeted approach allows for more precise delivery of the chemotherapy directly to the cancer cells, potentially reducing damage to healthy cells and minimizing side effects. Researchers are excited about this treatment because it offers a novel mechanism of action compared to conventional chemotherapy, which typically affects both cancerous and healthy cells indiscriminately. Additionally, Sacituzumab Govitecan has shown promise in patients who have not responded to other treatments, providing hope for those with limited options.

Studies have shown that sacituzumab govitecan effectively treats certain types of breast cancer. This treatment targets Trop-2, a protein often found in high amounts on cancer cells, and delivers a potent drug that halts cancer cell growth. Research indicates that sacituzumab govitecan can help patients live longer without disease progression and can also increase overall survival in patients with HR+/HER2- breast cancer. In some studies, patients treated with this drug achieved better results compared to other treatments. Although there is interest in using sacituzumab govitecan after trastuzumab deruxtecan, more specific evidence is needed for this sequence. Participants in this trial will receive sacituzumab govitecan as the investigational treatment.¹⁵⁶⁷⁸